Skip to main content

Table 2 Estimated risk of blindness per 1000 population in four scenarios based on high and low prevalence of loiasis and onchocerciasis, under conditions of: 1) no mass treatment with Mectizan®; 2) mass treatment with no risk reduction strategy; and 3) mass treatment using REA, RAPLOA-40, RAPLOA-20, or combined REA/RAPLOA-40 to reduce risk of L. loa encephalopathy.

From: A Framework for Decision-Making for Mass Distribution of Mectizan® in Areas Endemic for Loa loa

Loiasis Prevalence

High

High

Low

Low

Onchocerciasis Prevalence

High

Low

High

Low

No Mectizan® treatment

166.0

94.0

166.0

94.0

Mectizan® treatment

    

   No risk reduction strategy

58.1

32.9

58.1

32.9

   REA

58.7

35.5

58.7

35.5

   RAPLOA-40

58.1

32.9

58.1

32.9

   RAPLOA-20

58.1

32.9

58.1

32.9

   REA/RAPLOA-40

58.4

33.9

58.2

33.3